VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 333 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2016. The put-call ratio across all filers is 1.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $732,000 | -29.4% | 66,400 | -7.0% | 0.04% | -39.1% |
Q4 2016 | $1,037,000 | -38.4% | 71,400 | +4.1% | 0.07% | -34.9% |
Q3 2016 | $1,684,000 | +26.5% | 68,600 | +3.8% | 0.11% | +7.1% |
Q2 2016 | $1,331,000 | -40.8% | 66,100 | -22.7% | 0.10% | -47.3% |
Q1 2016 | $2,249,000 | -73.6% | 85,500 | +2.2% | 0.19% | -70.9% |
Q4 2015 | $8,508,000 | -57.6% | 83,700 | -25.6% | 0.64% | -60.4% |
Q3 2015 | $20,068,000 | -52.3% | 112,500 | -40.6% | 1.63% | -46.9% |
Q2 2015 | $42,042,000 | +36.6% | 189,250 | +22.1% | 3.07% | +6.6% |
Q1 2015 | $30,786,000 | +240.1% | 155,000 | +145.1% | 2.88% | +172.0% |
Q4 2014 | $9,052,000 | +23.2% | 63,250 | +12.9% | 1.06% | -6.9% |
Q3 2014 | $7,347,000 | +5.4% | 56,000 | +1.4% | 1.14% | -9.0% |
Q2 2014 | $6,968,000 | -0.3% | 55,250 | +4.2% | 1.25% | -22.5% |
Q1 2014 | $6,987,000 | +26.6% | 53,000 | +12.8% | 1.61% | -18.2% |
Q4 2013 | $5,518,000 | – | 47,000 | – | 1.97% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
Hound Partners | 3,898,648 | $695,441,000 | 15.04% |